Evidence map›Paper›PMID 40118048›Full record

ReviewCancer cell2025

Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit.

Kristen E Pauken, Omar Alhalabi, Sangeeta Goswami, Padmanee Sharma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kristen E PaukenDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omar AlhalabiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangeeta GoswamiDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: sgoswami@mdanderson.org.
Padmanee SharmaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: padsharma@mdanderson.org.

Funding

Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBMR37CA279192 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Sangeeta Goswami · 2023 to 2026
$1.9M
NCI NIH HHS R37 CA279192
6 · The paper itself

Abstract

While immune checkpoint therapy (ICT) has revolutionized cancer treatment, most patients with advanced disease fail to achieve durable benefit. To address this challenge, it is essential to integrate mechanistic research with clinical studies to: (1) understand response mechanisms, (2) identify patient-specific resistance pathways, (3) develop biomarkers for patient selection, and (4) design novel therapies to overcome resistance. We propose that incorporating "direct-in-patient" studies into clinical trials is crucial for bridging the gap between fundamental science and clinical oncology. In this review, we first highlight recent clinical success of ICT in the neoadjuvant setting, where treatment is given in earlier disease stages to improve outcomes. We then explore how neoadjuvant clinical trials could be utilized to drive mechanistic laboratory-based investigations. Finally, we discuss novel scientific concepts that will potentially aid in overcoming resistance to ICT, which will require future clinical trials to understand their impact on human immune responses.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyNeoadjuvant TherapyNeoplasmsClinical Trials as TopicDrug Resistance, NeoplasmHumansImmune Checkpoint Inhibitorsbiomarkersclinical trialsCTLA-4human immunologyimmune checkpoint therapyneoadjuvantPD-1

Identifiers

PMID40118048
PMCPMC13143226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.